Graves Disease Market size to Reach USD 2.87 Billion by 2031 Amid Rising Autoimmune Burden and Expanding Biologic Therapies

Introduction: 

According to Mordor Intelligence, the graves disease market size was valued at USD 2.15 billion in 2025 and is estimated to grow from USD 2.26 billion in 2026 to reach USD 2.87 billion by 2031, reflecting steady demand across diagnosis and treatment segments. The latest graves disease market forecast indicates consistent expansion supported by improved diagnostic access, wider biologic adoption, and evolving treatment pathways. 

Graves’ disease, an autoimmune disorder leading to hyperthyroidism, continues to create sustained demand across the healthcare system. The growing autoimmune disease burden, especially among women under forty and increasing pediatric incidence, supports long-term graves disease market growth. Healthcare providers are moving beyond symptom control toward targeted immunotherapies, influencing both graves' disease market share distribution and treatment preferences. 

Key Graves Disease Market Trends 

Rising Prevalence of Hyperthyroidism 

An increase in autoimmune thyroid disorders across developed and emerging economies remains a central driver of graves disease market trends. Improved screening programs and greater awareness are identifying cases earlier, particularly in iodine-sufficient regions. Pediatric diagnoses have also risen, widening the addressable patient base and influencing the long-term graves disease market forecast. 

Shift Toward Targeted Immunotherapies 

Biologic therapies targeting immune pathways are gradually gaining traction within the graves disease market. FcRn inhibitors and IGF-1R antagonists are changing treatment discussions, especially for patients who do not respond to conventional anti-thyroid drugs. This transition is reshaping graves disease market share, as biologics attract payer attention due to their disease-modifying potential. 

Continued Role of Radioactive Iodine Therapy 

Despite biologic expansion, radioactive iodine therapy remains relevant, particularly among elderly patients and those with cardiovascular risk. Hospitals continue to integrate radioiodine protocols into treatment algorithms, preserving a stable segment within the graves disease industry. However, isotope supply considerations influence regional availability and impact treatment choices. 

Expanding Reimbursement Coverage 

Private and public payers are gradually widening coverage for newer therapies, especially for thyroid eye disease associated with Graves’ disease. Broader reimbursement access strengthens graves disease market growth by supporting biologic uptake while maintaining traditional therapy usage. Funding support for rare autoimmune disorders further sustains demand across healthcare settings. 

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/graves-disease-market?utm_source=industrytoday  

Graves Disease Market Segmentation 

By Diagnosis 

• Thyroid Function Tests 
• Imaging 
• Antibody Testing 
• Other Diagnostic Methods 

By Treatment 

• Anti-Thyroid Medication 
• Radioactive Iodine Therapy 
• Surgery 
• Emerging Immunotherapies 

By Patient Age Group 

• Pediatrics 
• Adults 
• Geriatrics 

By End-User 

• Hospitals 
• Specialty Clinics 
• Ambulatory Surgical Centers 
• Retail and Online Pharmacies 

By Geography 

• North America 
• Europe 
• Asia-Pacific 
• Middle East and Africa 
• South America 

Explore Our Full Library of Healthcare Research Report: https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=industrytoday  

Competitive Landscape in the Graves Disease Industry 

The graves disease market reflects moderate competition, with established pharmaceutical companies and emerging biotech firms participating across diagnostics and therapeutics. Traditional endocrine portfolios continue to generate consistent revenue, while biologic-focused companies compete for share in targeted therapies. 

Key Players in the Graves Disease Market 

• Abbott Laboratories 
• F. Hoffmann-La Roche AG 
• Horizon Therapeutics plc 
• Immunovant Inc. 
• Pfizer Inc. 

Explore more insights on Graves Disease competitive landscape: https://www.mordorintelligence.com/industry-reports/graves-disease-market/companies?utm_source=industrytoday  

Conclusion 

The graves disease market is expected to maintain steady expansion as awareness improves and treatment pathways diversify. The transition toward targeted immunotherapies, alongside the continued role of conventional therapies, supports balanced graves disease market trends across regions. 

While cost pressures and supply constraints present operational challenges, expanding reimbursement coverage and improved diagnostic precision contribute positively to the graves disease market forecast. The evolving treatment landscape ensures that both traditional pharmaceutical players and biologic developers remain active participants in shaping the future of the graves disease industry. 

Get detailed insights on the Graves Disease market: https://www.mordorintelligence.com/industry-reports/graves-disease-market?utm_source=industrytoday   

Industry Related Reports 

Systemic Lupus Erythematosus Market: https://www.mordorintelligence.com/industry-reports/systemic-lupus-erythematosus-market?utm_source=industrytoday 

Osteoarthritis Treatment Market Size: https://www.mordorintelligence.com/industry-reports/osteoarthritis-treatment-market?utm_source=industrytoday 

Rheumatoid Arthritis Drugs Market Share: https://www.mordorintelligence.com/industry-reports/rheumatoid-arthritis-drugs-market?utm_source=industrytoday 

About Mordor Intelligence: 

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. 

For any inquiries or to access the full report, please contact: 

media@mordorintelligence.com 

https://www.mordorintelligence.com/